VeloClub is CyclingTips’ membership program which brings us closer to our members, and connects likeminded cycling enthusiasts.
by Neal Rogers
July 12, 2017
In today’s Daily News Digest: Kittel wins Stage 10 field sprint at Tour de France, his fourth at this year’s race; Is the battle for the Tour’s green jersey over?; Selig boosts morale at Bora-Hansgrohe with fourth-place sprint finish; Former Bora-Argon 18 rider Ralf Matzka positive for anti-estrogenic Tamoxifen; Cadel Evans Great Ocean Road Race women’s event to move up to UCI 1.1 status in 2018; Video: GoPro’s Tour de France Stage 10 highlights; Video: Kiwi George Bennett’s home away from home in Girona, Spain.
Former Bora-Argon 18 rider Ralf Matzka tested positive for the substance Tamoxifen in March 2016, Bora-Hansgrohe team manager Ralph Denk announced in a statement.
Matzka, who rode for Bora-Argon 18 from 2013 through 2016, tested positive for very small quantities of Tamoxifen, an anti-estrogenic which increases the production of testosterone. According to the statement, several independent experts came to the conclusion that the most likely reason for the substance in Matzka’s urine was contaminated water.
“After carefully reviewing the experts’ reports, the team Bora-Argon 18 took the decision not to publish the results at this time of the investigation to protect the
athlete,” Denk wrote. “An investigation procedure of the Frankfurt Prosecutor has been closed in September 2016 due to lack of suspicion. Until today the rider has not been suspended or banned by the UCI. The UCI has initiated internal proceedings and has taken legal actions. On the basis of the experts’ reports and all given facts at this point of time, the team expects a verdict of acquittal. The team will not give any further statements to the ongoing proceedings.”
Matzka, 27, was finished fourth in the 2014 Sparkassen Münsterland Giro and eighth at the 2014 Brussels Cycling Classic. He currently does not have a pro contract.